A method of modifying or altering the structured a 1.alpha.-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1.alpha.-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1.alpha.-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1.alpha.-hydroxyl in the axial orientation.

Un método de modificar o de alterar estructurado 1.alpha.-hydroxylated un compuesto de la vitamina D para aumentar su actividad biológica alterando el equilibrio del conformational del Uno-anillo para favorecer una conformación de la silla que presenta el 1.alpha.-hydroxyl en la orientación axial. Esto es lograda trabando la conformación de la silla del Uno-anillo en una geometría que tiene un 1.alpha.-hydroxyl axialmente orientado, o por la adición de unos o más sustitutos al Uno-anillo que interactivo con otros sustitutos en la molécula o en el Uno-anillo para proporcionar una fuerza impulsora al Uno-anillo para adoptar una conformación de la silla que presenta el 1.alpha.-hydroxyl en la orientación axial.

 
Web www.patentalert.com

< (none)

< Purchase and delivery of digital content using multiple devices and data networks

> Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine .beta.-3 adrenergic receptor agonists

> (none)

~ 00057